• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

A Comparative Study of the Effectiveness of 0.5% Ropivacaine Versus 0.5% Bupivacaine in Supraclavicular Brachial Plexus Block in Upper Limb Orthopaedic Surgeries

    Lakshmi.P. B, Madhusoodanan pillai.C, Susan Suku Ninan

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 10860-10864

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Brachial plexus block provides surgical anaesthesia and analgesia and also provides postoperative analgesia. Nowadays regional blocks are increasingly used because of a higher success rate due to USG guidance and peripheral nerve stimulators.  Regional blocks overcome the disadvantages of general anaesthesia like upper airway instrumentation and the use of multiple drugs. The supraclavicular approach for brachial plexus is the most consistent method of analgesia below the shoulder joint. Commonly used local anaesthetics are lignocaine and Bupivacaine. Ropivacaine is an amide local anaesthetic drug. The lower cardiotoxic potential, more rapid clearance and reduced motor block seen with Ropivacaine compared to Bupivacaine is advantageous especially when larger doses are required. The aim of my study is to assess the effectiveness of Ropivacaine compared to Bupivacaine in supraclavicular brachial plexus block.
Materials and methods: 100 patients in the age group 20 to 65 years were divided into two groups of 50 each. Group A received 25 ml of 0.5%Bupivacaine. Group B received 25 ml of 0.5% Ropivacaine. The total dose was not exceeded the recommended dose as per the body weight.
Results: Duration of analgesia was prolonged in Ropivacaine group (550.4+/_26.3 minutes) compared to Bupivacaine group (450.7+/-26.9 minutes). Duration of motor block was comparable in both groups.
Conclusion: Ropivacaine has advantages over Bupivacaine for supraclavicular block due to its long analgesic duration without significant side effects.
Keywords:
  • PDF (161 K)
  • XML
(2022). A Comparative Study of the Effectiveness of 0.5% Ropivacaine Versus 0.5% Bupivacaine in Supraclavicular Brachial Plexus Block in Upper Limb Orthopaedic Surgeries. European Journal of Molecular & Clinical Medicine, 9(3), 10860-10864.
Lakshmi.P. B, Madhusoodanan pillai.C, Susan Suku Ninan. "A Comparative Study of the Effectiveness of 0.5% Ropivacaine Versus 0.5% Bupivacaine in Supraclavicular Brachial Plexus Block in Upper Limb Orthopaedic Surgeries". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 10860-10864.
(2022). 'A Comparative Study of the Effectiveness of 0.5% Ropivacaine Versus 0.5% Bupivacaine in Supraclavicular Brachial Plexus Block in Upper Limb Orthopaedic Surgeries', European Journal of Molecular & Clinical Medicine, 9(3), pp. 10860-10864.
A Comparative Study of the Effectiveness of 0.5% Ropivacaine Versus 0.5% Bupivacaine in Supraclavicular Brachial Plexus Block in Upper Limb Orthopaedic Surgeries. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 10860-10864.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 76
  • PDF Download: 103
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus